AbbVie Plans to Expand in the Obesity Treatment Market

Glonghui, January 15th | AbbVie stated that the company is seeking to expand its share in the rapidly growing obesity treatment market, mainly relying on a weight-loss drug licensed last year from the Danish biotechnology company Gubra. Gubra’s drug, GUBamy, mimics the amylin hormone and is expected to become an alternative therapy to commonly used GLP-1 drugs such as Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound, helping patients achieve better weight loss results with fewer side effects. AbbVie’s Chief Medical Officer Roopal Thakkar said at the J.P. Morgan Healthcare Conference that the company is focusing on studying the tolerability and durability of weight loss with GUBamy in patients who have developed resistance to first-generation therapies.